Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2017

Description: Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2017, provides an overview of the Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline landscape.

Proliferative Vitreoretinopathy (PVR) occurs when a scar forms under or on the retina after retinal detachment, preventing the retina from healing and falling back into place. Risk factors for proliferative vitreoretinopathy include bleeding within the eye, increased inflammation from trauma, high degree myopia (short-sightedness), family history, severe inflammation or complications from diabetes.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Proliferative Vitreoretinopathy (PVR) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Vitreoretinopathy (PVR) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Proliferative Vitreoretinopathy (PVR) (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Proliferative Vitreoretinopathy (PVR) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Proliferative Vitreoretinopathy (PVR) (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Proliferative Vitreoretinopathy (PVR) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Proliferative Vitreoretinopathy (PVR) (Ophthalmology)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Proliferative Vitreoretinopathy (PVR) (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents:

Introduction
Proliferative Vitreoretinopathy (PVR) - Overview
Proliferative Vitreoretinopathy (PVR) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Proliferative Vitreoretinopathy (PVR) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Proliferative Vitreoretinopathy (PVR) - Companies Involved in Therapeutics Development
Novartis AG
Promedior Inc
RXi Pharmaceuticals Corp
Proliferative Vitreoretinopathy (PVR) - Drug Profiles
Antisense RNAi Oligonucleotide to Inhibit CTGF for PVR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Inhibit TAK1 for Proliferative Vitreoretinopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRM-167 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Hdm2 for Proliferative Vitreoretinopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XOMA-089 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proliferative Vitreoretinopathy (PVR) - Dormant Projects
Proliferative Vitreoretinopathy (PVR) - Product Development Milestones
Featured News & Press Releases
Apr 27, 2015: RXi Pharmaceuticals Announces Upcoming Presentations at Leading Partnering and Scientific Conferences
May 22, 2014: RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering Technology Platform
May 07, 2012: Promedior Presents Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting
May 01, 2012: Promedior To Present Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables:
Number of Products under Development for Proliferative Vitreoretinopathy (PVR), H1
Number of Products under Development by Companies, H1
Number of Products under Development by Universities/Institutes, H1
Products under Development by Companies, H1
Products under Development by Universities/Institutes, H1
Number of Products by Stage and Target, H1
Number of Products by Stage and Mechanism of Action, H1
Number of Products by Stage and Route of Administration, H1
Number of Products by Stage and Molecule Type, H1
Proliferative Vitreoretinopathy (PVR) - Pipeline by Novartis AG, H1
Proliferative Vitreoretinopathy (PVR) - Pipeline by Promedior Inc, H1
Proliferative Vitreoretinopathy (PVR) - Pipeline by RXi Pharmaceuticals Corp, H1
Proliferative Vitreoretinopathy (PVR) - Dormant Projects, H1

List of Figures:
Number of Products under Development for Proliferative Vitreoretinopathy (PVR), H1
Number of Products under Development by Companies, H1
Number of Products by Targets, H1
Number of Products by Stage and Targets, H1
Number of Products by Mechanism of Actions, H1
Number of Products by Stage and Mechanism of Actions, H1
Number of Products by Molecule Types, H1
Number of Products by Stage and Molecule Types, H

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/4189172/](http://www.researchandmarkets.com/reports/4189172/)
Order by Fax - using the form below
Order by Post - print the order form below and send to
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2017
Web Address: http://www.researchandmarkets.com/reports/4189172/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Single User</th>
<th>Enterprisewide</th>
<th>Site License</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td>USD 2000</td>
<td>USD 6000</td>
<td>USD 4000</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by Wire Transfer: Bank details will be provided on the invoice which you will receive after you place your order with us.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World